Letters to the Editor

1. Allan DS, Buckstein R, Imrie KR. Outpatient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk Lymphoma 2001;42:339-46.
2. Kern WV. Outpatient management in patients with neutropenia after intensive chemotherapy: is it safe? Ann Oncol 2005;16:179-80.
3. Cherif H, Johansson E, Bjorkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 2006;91:215-22.
4. Savoie ML, Nevil TJ, Song KW, Morano SG, Celesti F, Coppola L, et al. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol 2006;17:763-8.
5. Girmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L, et al. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica 1999;84:814-9.
6. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
7. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;35:720-51.
8. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107:1747-51.
9. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95.
10. Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis 2001;33:139-44.
11. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004;33:735-9.

Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only

We report the outcome of Dutch pediatric relapsed AML patients and focus on patients treated with chemotherapy alone. Median time from first complete remission to relapse was nine months. Second complete remission (CR2) was achieved in 63%. Overall, only 16% of patients were survivors. When only patients who achieved CR2 were analyzed, 50% of the patients treated with allogeneic stem cell transplantation and 24% of the patients treated with chemotherapy alone, were long-term survivors.

The prognosis of children with acute myeloid leukemia (AML) has improved markedly over the last decades with 5-year overall survival rates (5-year pOS) in the most recent treatment protocols as high as 50-60%.

In the Netherlands, children with AML are treated according to protocols developed by the Dutch Childhood Oncology Group (DCOG). Since 1980, four protocols for the treatment of childhood AML have been completed, and overall survival has improved from 18% to 42%.

Relapse remains the most frequent cause of treatment failure, with a cumulative risk of relapse of 30-40% in most pediatric AML studies. In the consecutive Dutch AML protocols, the cumulative risk of relapse was 60, 43, 47 and 26% respectively. Allogeneic stem cell transplantation (alloSCT) is generally recommended as part of treatment of relapsed AML. Formal evidence for this recommendation is lacking, despite evidence of a graft-versus-leukemia effect in AML. At initial diagnosis of high-risk AML, alloSCT seems no better than chemotherapy only. Therefore, the need for alloSCT in relapsed AML may be questioned, at least as a general recommendation.

We studied all Dutch children and adolescents with AML that were initially diagnosed and treated between 1980 and 1998 and relapsed before 1st January 2007. The patients were initially treated according to the Dutch Childhood Oncology Group (DCOG) protocols AML-80, AML-82, AML-87 and AML-92/94. We focused on patients reported to be alive without disease after treatment with chemotherapy only for their relapse and summarized the relevant literature. Since autologous SCT has been reported to provide similar results to intensive chemotherapy, and does not have a graft-versus-leukemia effect, these patients (n=9) were included in the chemotherapy only group. Most patients were treated with a reinduction regimen containing cytarabine, most frequently in combination with an anthracycline and etoposide.

A total of 113 relapsed AML cases were identified, with a median time from first complete remission (CR1) to relapse of nine months (range 1-61 months). Ninety of these patients were treated with curative intent and CR2 was achieved in 63%. In univariate analysis, sex, age, WBC, FAB-type and SCT in CR1 were not associated with achievement of CR2. None of the patients who failed to achieve remission on first-line treatment when treated for their initially diagnosed AML (n=11) achieved CR2, compared to 72% of patients who did achieve CR1 on first-line treatment ($p<0.0001$). CR1 duration (CR1<1 year or CR1>1 year) correlated significantly with the probability of achieving CR2 (55 vs. 76%, $p=0.04$) and 10-year pOS (15 vs. 30%, $p=0.02$) in univariate analysis. The overall 10-year pOS was 16% (standard error (SE) 3%), with 18 disease-free long-term survivors.

AlloSCT was performed in 16 out of the 57 CR2 patients, with 8 (50%) long-term survivors. Ten out of the 41 patients (24%) treated without alloSCT survived. This comparison is biased by the fact that to be able to undergo SCT, it is necessary to have a suitable donor, to maintain CR2 until the SCT and to be in a relatively good condition. In multivariate analysis using Cox-regression, we corrected alloSCT in CR2 for time to transplant. In this analysis of pOS alloSCT was not an independent favorable prognostic factor ($HR=0.56$, 95% confidence interval (CI) 0.26-1.24, $p=0.15$), as was also the case for CR1 duration ($HR=1.5$, 95% CI 0.78-2.88, $p=0.23$). This study was limited by its retrospective nature, the diverse treatment schedules used, and the relatively small number of patients, especially when prognostic factors were analyzed. The 10 long-term survivors treated at relapse without alloSCT (7 chemotherapy only, plus 3 auto-SCT) did not have unique or similar clinical or cell biological features and included 6 patients with relapse within 12 months from CR1 (Table 1). Some of these 10 patients had been treated in the 1990s with relatively intensive chemotherapy at initial diagnosis. In 10 out of 18 survivors, late effects of treatment were reported such as...
Letters to the Editor

Secondary malignancies, hypogonadotropic hypogonadism and neurological problems. Late effects were more frequently reported in children who received a SCT than in children who did not, with 9/12 patients who were treated with SCT reporting late effects, compared to 1/6 patients treated with chemotherapy alone ($\chi^2 p=0.019$). In the literature, 6 papers describe the outcome of cohorts of pediatric relapsed AML patients (Table 2).\(^a\)\(^b\)

Overall probabilities of survival at 2-5 years ranged from 12% to 34%. Including the patients in this study, 109 relapsed pediatric AML patients treated with chemotherapy alone were reported in literature and 34 of these 91 patients were reported as survivors (31%), which is surprisingly high. However, patient selection may have occurred, and some patients may not have received optimal treatment at initial diagnosis according to current standards.

Based on these results, we question whether an alloSCT in CR2 is the only chance of cure for children with relapsed AML, as is commonly thought.\(^c\)\(^d\) A randomized clinical trial to prove this has never been performed. Especially when a matched donor is unavailable, intensive chemotherapy may be preferable over a mismatched or haplo-identical donor SCT, which is associated with significant morbidity and mortality.\(^e\)\(^f\)\(^g\)\(^h\)\(^i\)\(^j\) Currently, however, it is not known how to identify the patients who do

### Table 1. Long-term survivors of pediatric relapsed AML after treatment with chemotherapy alone.

| UPN | Relapse site | Age (yr) | Sex | FAB | Cytogenetics | Initial treatment | SCT in CR1 (m) | CR1 | Relapse treatment | SCT in CR2 | Events in CR2 | Follow-up (m) |
|-----|-------------|----------|-----|-----|-------------|------------------|---------------|-----|-----------------|------------|---------------|---------------|
| 1   | BM          | 14.0     | f   | M1  | t(3;5)      | DA               | No            | 33  | I: AML82 induction | Auto      | No            | 151           |
| 2   | BM          | 9.8      | m   | M3  | t(15;17)    | DA               | No            | 27  | I: HD araC          | No         | No            | 171           |
| 3   | CNS         | 1.0      | m   | M5  | Normal      | I: dnr, vcr, pred| No            | 9   | araC i.th. 1x/wk.  | No         | No            | 176           |
| 4   | BM          | 4.1      | m   | AUL | Complex     | ALL, later AML80 | No            | 7   | I: DAT             | No         | No            | 183           |
| 5   | BM/skin     | 1.2      | f   | M5  | Unknown     | AML82            | No            | 4   | I: unknown         | No         | No            | 113           |
| 6   | BM/CNS      | 11.3     | f   | M4  | Inv(16)     | AML82            | MSD           | 10  | I: AML-BFM87 without M | No         | No            | 208           |
| 7   | BM          | 13.2     | f   | M5  | Unknown     | AML87            | No            | 10  | I: ADE, pred, cyclo | Auto relapse chemotherapy: CR3 | No  | 183           |
| 8   | BM          | 15.8     | f   | M6  | Unknown     | AML87            | No            | 25  | araC, dox, vp16, 6TG, vcr | No         | No            | 183           |
| 9   | BM          | 4.8      | m   | M2au| Unknown     | AML87            | No            | 13  | I: AE, intensification HD araC and ifos | No         | No            | 100           |
| 10  | CNS         | 3.1      | m   | M5  | 11q23 abn   | AML87            | No            | 4   | araC, vcr, 6MP + RT CNS, i.th. araC, pred. | No         | No            | 92            |

**UPN**: unique patient number; **yr**: year; **FAB**: French-American-British; **SCT**: stem cell transplantation; **CR1**: first complete remission; **CR2**: second complete remission; **m**: months; **BM**: bone marrow; **CNS**: central nervous system; **m**: male; **f**: female; **DA**: daunorubicin and cytarabine; **I**: induction; **M**: maintenance; **dnr**: daunorubicin; **vcr**: vincristine; **pred**: prednisolon; **araC**: cytarabine; **vp16**: etoposide; **cyclo**: cyclophosphamide; **MSD**: matched sibling donor; **HD**: high-dose; **6MP**: 6-mercaptopurine; **i.th.**: intrathecal; **DAT**: daunorubicin, cytarabine and 6-thioguanine; **ADE**: cytarabine, daunorubicin, etoposide; **ifos**: ifosfamide; **6TG**: 6-thioguanine; **LD**: low-dose; **RT**: radiotherapy; **Auto**: autologous; **CR3**: third complete remission.

### Table 2. Reports of the outcome of children with relapsed AML.

| Initial study (time period) (reference) | Time Period | Survival | Survival with chemotherapy alone |
|----------------------------------------|-------------|----------|---------------------------------|
| AML-BFM\(^a\)                          | 1987-1996   | 5-year p0S 21% | 55% (5/9)                        |
| CCG-251/213/2861\(^i\)                 | 1979-1989   | 3-year p0S 12%* | Unknown                          |
| CCG-2891\(^i\)                         | 1989-1995   | 3-year p0S 17%* | Unknown                          |
| CCG-2951\(^i\)**                      | 1997-2001   | 2-year p0S 24% | 62% (8/13)                      |
| DCOS AML 80/82/87/9294                 | 1980-1998   | 10-year p0S 16% | 24% (10/41)                     |
| LAME 89/91\(^i\)                       | 1988-1998   | 5-year p0S 33% | 100% (3/3)                      |
| MRC AML 10\(^i\)                       | 1988-1995   | 3-year p0S 24% | 18% (3/17)                      |
| NOPHO AML 88/93\(^i\)                 | 1998-2003   | 5-year p0S 34% | 44% (8/18)                      |
| St. Jude Children’s Hospital AML 87/91/97\(^i\) | 1987-2002   | 5-year p0S 23% | 0% (0/17)                       |

p0S: probability of overall survival. *Also included non-remitters. **Pediatric relapsed AML study.
not need an alloSCT for cure after relapse. Results of the ongoing International BFM Study Group Pediatric Relapsed AML protocol, will contribute to this discussion in the near future. The Dutch and literature data suggest that randomized studies of the role of alloSCT in subgroups of relapsed AML are required. Meanwhile, experimental allogeneic SCT procedures, such as haplo-identical and mismatched unrelated donor SCT, should be carefully balanced against the chance of cure by chemotherapy only in patients in good quality second complete remission of AML.

Bianca F. Goemans,1 Rienk Y.J. Tamminga,1,2 Carin M. Corbijn,1 Karel Hühlen,1,2 Gertjan J.L. Kaspers1

1Department Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam; 2Department Childhood Oncology Group (DCOG), the Hague; 3Department Pediatric Oncology/Hematology, Beatrix Children’s Hospital, UMCG, Groningen; 4Department Pediatric Oncology/Hematology, Sophia Children’s Hospital, Erasmus MC, Rotterdam, the Netherlands

Key words: acute myeloid leukemia, relapse, chemotherapy, stem cell transplantation

Correspondence: Bianca F. Goemans, MD, PhD, Department Pediatric Oncology/Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Phone: international +31.20.4442420. Fax: international +31.20.4442422. E-mail: bf.goemans@vumc.nl

Citation: Goemans BF Tamminga RYJ, Korbijn CM, Hühlen K, Kaspers GJL. Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only. Haematologica 2008; 93:1418-1420. doi: 10.3324/haematol.12807.

The International Prognostic Scoring System for Waldenström’s macroglobulinemia is applicable in patients treated with rituximab-based regimens

Waldenström’s macroglobulinemia (WM) is characterized by lymphoplasmacytic bone marrow infiltration and by production of serum monoclonal IgM. This disease usually follows a relatively indolent course with a median survival ranging from 60 months to 120 months in different series. However, in some patients the disease may be more aggressive causing their death within months. Several analyses have identified variables that may be associated with a worse prognosis. These include advanced age, cytopenia(s), hypoalbuninemia, elevated serum β2-microglobulin, high IgM, poor performance status, B-symptoms or splenomegaly. Recently, a multicenter collaborative project was undertaken which included a large number of previously untreated, symptomatic patients who required treatment. An International Prognostic Scoring System for WM (IPSSWM) was formulated based on 5 adverse covariates: age >65 years, hemoglobin ≤11.5 g/dL, platelet count ≤100×10^9/L, β2-microglobulin >3 mg/L and serum monoclonal protein concentration >70 g/L. Low risk is defined by the presence of ≤1 adverse variable except age, high risk by the presence of >2 adverse characteristics and intermediate risk by the presence of 2 adverse characteristics or age >65 years; 5-year survival rates are 87%, 68% and 36% respectively. However, 96% of the patients included in this analysis had received frontline treatment with alkylating agents or nucleoside analogs. Since rituximab-based regimens are now frequently used as a frontline treatment in WM patients, we analyzed whether the IPSSWM can be applied in these patients.

Ninety-three previously untreated, symptomatic patients who received treatment either with single agent rituximab (21 patients) or with the combination of dexamethasone, rituximab and cyclophosphamide (72 patients), formed the basis of this analysis. This analysis was approved by the Institutional Review Board. These patients were included in two trials reported previous-